Cargando…

Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases

BACKGROUND: There are concerns about a link between the ChAdOx1 nCoV-19 and Ad26.COV2.S vaccines against COVID-19 and cerebral venous thrombosis (CVT) and other thrombotic events. One key missing component of the risk-benefit analysis of using such vaccines is the risk of these severe thrombotic eve...

Descripción completa

Detalles Bibliográficos
Autores principales: Taquet, Maxime, Husain, Masud, Geddes, John R, Luciano, Sierra, Harrison, Paul J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324974/
https://www.ncbi.nlm.nih.gov/pubmed/34368663
http://dx.doi.org/10.1016/j.eclinm.2021.101061
_version_ 1783731474873188352
author Taquet, Maxime
Husain, Masud
Geddes, John R
Luciano, Sierra
Harrison, Paul J
author_facet Taquet, Maxime
Husain, Masud
Geddes, John R
Luciano, Sierra
Harrison, Paul J
author_sort Taquet, Maxime
collection PubMed
description BACKGROUND: There are concerns about a link between the ChAdOx1 nCoV-19 and Ad26.COV2.S vaccines against COVID-19 and cerebral venous thrombosis (CVT) and other thrombotic events. One key missing component of the risk-benefit analysis of using such vaccines is the risk of these severe thrombotic events following COVID-19. METHODS: Using a retrospective cohort study based on electronic health records primarily in the USA, the absolute risks of CVT and portal vein thrombosis (PVT) in the two weeks following a diagnosis of COVID-19 (made between January 20, 2020 and March 25, 2021) were calculated. The risks were compared to cohorts of patients with influenza (diagnosed within the same period) and people receiving an mRNA vaccine (i.e. not the ChAdOx1 nCoV-19 and Ad26.COV2.S vaccines) against COVID-19 (matched for demographics and the main risk factors for CVT and PVT). FINDINGS: A total of 537,913 patients with a COVID-19 diagnosis were included. The incidence of CVT in the two weeks after a COVID-19 diagnosis was 42.8 per million people (95% CI 28.5–64.2). This was significantly higher than in a matched cohort of people who received an mRNA vaccine (RR = 6.33, 95% CI 1.87–21.40, P = 0.00014) and patients with influenza (RR = 2.67, 95% CI 1.04–6.81, P = 0.031). The incidence of PVT after COVID-19 diagnosis was 392.3 per million people (95% CI 342.8–448.9). This was significantly higher than in a matched cohort of people who received an mRNA vaccine (RR=4.46, 95% CI 3.12–6.37, P < 0.0001) and patients with influenza (RR=1.43, 95% CI 1.10–1.88, P = 0.0094).
format Online
Article
Text
id pubmed-8324974
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83249742021-08-02 Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases Taquet, Maxime Husain, Masud Geddes, John R Luciano, Sierra Harrison, Paul J EClinicalMedicine Research Paper BACKGROUND: There are concerns about a link between the ChAdOx1 nCoV-19 and Ad26.COV2.S vaccines against COVID-19 and cerebral venous thrombosis (CVT) and other thrombotic events. One key missing component of the risk-benefit analysis of using such vaccines is the risk of these severe thrombotic events following COVID-19. METHODS: Using a retrospective cohort study based on electronic health records primarily in the USA, the absolute risks of CVT and portal vein thrombosis (PVT) in the two weeks following a diagnosis of COVID-19 (made between January 20, 2020 and March 25, 2021) were calculated. The risks were compared to cohorts of patients with influenza (diagnosed within the same period) and people receiving an mRNA vaccine (i.e. not the ChAdOx1 nCoV-19 and Ad26.COV2.S vaccines) against COVID-19 (matched for demographics and the main risk factors for CVT and PVT). FINDINGS: A total of 537,913 patients with a COVID-19 diagnosis were included. The incidence of CVT in the two weeks after a COVID-19 diagnosis was 42.8 per million people (95% CI 28.5–64.2). This was significantly higher than in a matched cohort of people who received an mRNA vaccine (RR = 6.33, 95% CI 1.87–21.40, P = 0.00014) and patients with influenza (RR = 2.67, 95% CI 1.04–6.81, P = 0.031). The incidence of PVT after COVID-19 diagnosis was 392.3 per million people (95% CI 342.8–448.9). This was significantly higher than in a matched cohort of people who received an mRNA vaccine (RR=4.46, 95% CI 3.12–6.37, P < 0.0001) and patients with influenza (RR=1.43, 95% CI 1.10–1.88, P = 0.0094). Elsevier 2021-07-31 /pmc/articles/PMC8324974/ /pubmed/34368663 http://dx.doi.org/10.1016/j.eclinm.2021.101061 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Taquet, Maxime
Husain, Masud
Geddes, John R
Luciano, Sierra
Harrison, Paul J
Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases
title Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases
title_full Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases
title_fullStr Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases
title_full_unstemmed Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases
title_short Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases
title_sort cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 covid-19 cases
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324974/
https://www.ncbi.nlm.nih.gov/pubmed/34368663
http://dx.doi.org/10.1016/j.eclinm.2021.101061
work_keys_str_mv AT taquetmaxime cerebralvenousthrombosisandportalveinthrombosisaretrospectivecohortstudyof537913covid19cases
AT husainmasud cerebralvenousthrombosisandportalveinthrombosisaretrospectivecohortstudyof537913covid19cases
AT geddesjohnr cerebralvenousthrombosisandportalveinthrombosisaretrospectivecohortstudyof537913covid19cases
AT lucianosierra cerebralvenousthrombosisandportalveinthrombosisaretrospectivecohortstudyof537913covid19cases
AT harrisonpaulj cerebralvenousthrombosisandportalveinthrombosisaretrospectivecohortstudyof537913covid19cases